Digest Network Come funziona
Network
/
Società
DB
Non verificato

DBV Technologies S.A.

Di cosa scriviamo

BiotecnologiaPolitica Internazionale

83 comunicati stampa

Guarda tutti i comunicati
16/12/2025
Biotecnologia
Politica Internazionale
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
16/12/2025
Biotecnologia
Politica Internazionale
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
02/12/2025
Biotecnologia
Politica Internazionale
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
02/12/2025
Biotecnologia
Politica Internazionale
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
11/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
11/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
04/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
04/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnologia
Politica Internazionale
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
Fonte
DBV Technologies S.A.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0